Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated MelanomaJames Larkin, Antoni Ribas, Paolo A. Ascierto et al.|New England Journal of Medicine|2014Cited by 2k
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trialPeter B. Gilbert, David C. Montefiori, Adrian B. McDermott et al.|Science|2022Cited by 1.2k
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trialPaolo A. Ascierto, James Larkin, Grant A. McArthur et al.|The Lancet Oncology|2016Cited by 1k
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a studyVolkan Granit, Matthew T. Duvernay, Adam Chowdhury et al.|The Lancet Neurology|2023Cited by 255
5-Year Outcomes with Cobimetinib plus Vemurafenib in <i>BRAF</i> V600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM StudyPaolo A. Ascierto, Grant A. McArthur, Brigitte Dréno et al.|Clinical Cancer Research|2021Cited by 182